R&G PharmaStudies Co., Ltd. (SHE:301333)
China · Delayed Price · Currency is CNY 62.13
+2.05 (3.41%)
Mar 27, 2026, 4:00 PM EDT
R&G PharmaStudies Market Cap
R&G PharmaStudies has a market cap or net worth of 5.91 billion as of March 27, 2026. Its market cap has increased by 17.34% in one year.
Market Cap
5.91B
Enterprise Value
4.22B
Revenue
851.01M
Ranking
n/a
PE Ratio
43.45
Stock Price
62.13
Market Cap Chart
Since August 2, 2022, R&G PharmaStudies's market cap has increased from 5.40B to 5.91B, an increase of 9.45%. That is a compound annual growth rate of 2.50%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 27, 2026 | 5.91B | 4.33% |
| Dec 31, 2025 | 5.67B | 19.12% |
| Dec 31, 2024 | 4.76B | -23.17% |
| Dec 29, 2023 | 6.19B | 25.30% |
| Dec 30, 2022 | 4.94B | -8.52% |
| Aug 2, 2022 | 5.40B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Wuhan Keqian Biology Co.,Ltd | 6.82B |
| Jiangsu Aidea Pharmaceutical Group | 6.74B |
| Shenzhen Weiguang Biological Products | 6.24B |
| Xiangxue Pharmaceutical | 6.23B |
| GemPharmatech | 6.00B |
| Lifecome Biochemistry | 5.92B |
| Beijing Konruns Pharmaceutical | 5.85B |
| Shanghai OPM Biosciences | 5.80B |